PureTech Health (PRTC) Competitors GBX 117.20 -21.00 (-15.20%) As of 11:51 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesBuy This Stock PRTC vs. GNS, ONT, ERGO, SLN, OXB, HZD, FARN, VRP, ARIX, and 4BBShould you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. PureTech Health vs. Genus Oxford Nanopore Technologies Ergomed Silence Therapeutics Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience 4basebio Genus (LON:GNS) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability. Do institutionals & insiders hold more shares of GNS or PRTC? 77.8% of Genus shares are held by institutional investors. Comparatively, 79.9% of PureTech Health shares are held by institutional investors. 0.8% of Genus shares are held by company insiders. Comparatively, 15.9% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend GNS or PRTC? Genus currently has a consensus target price of GBX 2,150, suggesting a potential upside of 26.03%. PureTech Health has a consensus target price of GBX 455, suggesting a potential upside of 288.23%. Given PureTech Health's higher probable upside, analysts clearly believe PureTech Health is more favorable than Genus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GNS or PRTC more profitable? Genus has a net margin of 1.18% compared to PureTech Health's net margin of -17,620.94%. Genus' return on equity of 1.41% beat PureTech Health's return on equity.Company Net Margins Return on Equity Return on Assets Genus1.18% 1.41% 3.31% PureTech Health -17,620.94%-21.15%-13.39% Does the media refer more to GNS or PRTC? In the previous week, Genus and Genus both had 3 articles in the media. Genus' average media sentiment score of 0.25 beat PureTech Health's score of -0.33 indicating that Genus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genus 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, GNS or PRTC? Genus has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenus£666.67M1.68£7.87M£12.06141.41PureTech Health£521.32K675.30-£91.86M-£24.38-4.81 Does the MarketBeat Community prefer GNS or PRTC? PureTech Health received 178 more outperform votes than Genus when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 70.54% of users gave Genus an outperform vote. CompanyUnderperformOutperformGenusOutperform Votes35270.54% Underperform Votes14729.46% PureTech HealthOutperform Votes53086.60% Underperform Votes8213.40% Which has more volatility and risk, GNS or PRTC? Genus has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. SummaryGenus beats PureTech Health on 9 of the 16 factors compared between the two stocks. Remove Ads Get PureTech Health News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTC vs. The Competition Export to ExcelMetricPureTech HealthBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£352.05M£112.73M£5.10B£2.35BDividend YieldN/A3.69%5.00%4.95%P/E Ratio-4.813.0720.52116.54Price / Sales675.303,893.34349.71243,032.23Price / Cash2.1413.0138.1527.90Price / Book1.0332.496.044.31Net Income-£91.86M-£87.82M£3.19B£5.78B7 Day Performance-20.27%-3.30%-7.79%-5.17%1 Month Performance-13.95%55.85%-6.82%-5.64%1 Year Performance-45.61%71.55%0.26%96.34% PureTech Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTCPureTech Health1.6511 of 5 starsGBX 117.20-15.2%GBX 455+288.2%-36.6%£352.05M£521,320.79-4.81300News CoverageGap DownHigh Trading VolumeGNSGenus1.9138 of 5 starsGBX 1,854-0.5%GBX 2,150+16.0%-1.3%£1.21B£666.67M153.68480Positive NewsONTOxford Nanopore Technologies1.5588 of 5 starsGBX 101.74-0.5%GBX 227.50+123.6%-12.1%£965.56M£184.78M-5.481,281Positive NewsERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumeOXBOxford BiomedicaN/AGBX 296.50-0.8%GBX 560+88.9%+21.6%£315.18M£98.31M-2.20891High Trading VolumeHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 207.60-2.5%N/A+62.3%£278.71MN/A-5.5534Gap UpVRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.9194BB4basebio2.3434 of 5 starsGBX 1,150+1.8%GBX 1,600+39.1%+26.7%£147.32M£311,000.00-1,474.36101High Trading Volume Remove Ads Related Companies and Tools Related Companies GNS Competitors ONT Competitors ERGO Competitors SLN Competitors OXB Competitors HZD Competitors FARN Competitors VRP Competitors ARIX Competitors 4BB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PRTC) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersDividend cuts are destroying retirements… is yours next?The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWill the U.S. military protect this $10B gold mine?You don’t need the gold price to move another inch for this company to potentially re-rate several hundred per...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Share PureTech Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.